Vericel (US:VCEL) Globenewswire·2026-01-13 14:00Core Insights - Vericel Corporation expects total revenue of approximately $276 million for the fourth quarter of 2025, with MACI revenue projected at $239.5 million, indicating a growth of 23% in both total revenue and MACI revenue compared to the previous year [1][6]. Financial Performance - The company anticipates a gross margin of 74% and an adjusted EBITDA margin of 26% for the fourth quarter [6]. - Vericel is expected to report GAAP net income profitability for the second consecutive year [6]. - The company holds $200 million in cash and investments with no debt [6]. Product and Market Developments - The fourth quarter of 2025 saw the highest number of MACI implants and trained surgeons since the product's launch, with MACI revenue growth exceeding 20% for the third consecutive year [6]. - Vericel has completed the expansion of its MACI sales force and has over 900 trained surgeons as of year-end 2025 [6]. - The company has initiated the MACI Ankle™ MASCOT clinical study and is on track to begin MACI commercial manufacturing in a new facility in 2026 [6]. Leadership Commentary - Nick Colangelo, President and CEO, stated that the company executed extremely well in 2025 and is entering 2026 with strong momentum, expecting continued high revenue growth and increased MACI utilization [3].